CTOs on the Move

Neurelis

www.neurelis.com

 
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neurelis.com
  • 11682 El Camino Real Suite 255
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Neurelis raised $114M on 03/10/2021

Similar Companies

US Eye

Be a part of something bigger. Enhance your eye care practice’s capabilities by partnering with a team that understands your business. Contact us today.

growve

Growve is a company that specializes in acquiring, operating, and growing world class brands in the supplements & active nutrition, beauty & personal care, home & leisure, lifestyle foods, and pet care verticals.

AlliancePharma

The vision of AlliancePharma Inc. is to offer a service that is human, professional and personalized, and fosters the development of the skills of the replacement pharmacists and pharmacy technicians. In the long term, AlliancePharma Inc. strives to increase and improve the value of its privileged position in the area of pharmacy replacement services, as well as diversifying its activities in high value added sectors linked to health.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.